[Celiprolol in acute myocardial infarct]

Area of Science:

• Cardiology
• Pharmacology

Background:

• Acute myocardial infarction (AMI) is associated with a high risk of ventricular arrhythmias.
• Beta-blockers are commonly used in AMI management, but their efficacy in preventing arrhythmias can vary.
• Celiprolol is a cardioselective beta-blocker with intrinsic sympathomimetic activity (ISA).

Purpose of the Study:

• To investigate the effect of celiprolol on the incidence of ventricular arrhythmias in patients with acute myocardial infarction (AMI).

Main Methods:

• A randomized trial comparing celiprolol (100 mg oral dose) with placebo, initiated 6 hours after symptom onset in AMI patients.
• Arrhythmia analysis was performed using Holter recordings and a Pathfinder system.
• Blood celiprolol levels were measured using High-Performance Liquid Chromatography (HPLC).

Main Results:

• No significant difference in Lown arrhythmia class distribution was observed between the celiprolol and placebo groups.
• Ventricular premature contraction (VPC) rates were slightly higher initially in the celiprolol group, with similar decreasing trends over time in both groups.
• No instances of ventricular fibrillation occurred in either group.

Conclusions:

• Celiprolol did not demonstrate a beneficial effect on ventricular arrhythmias in AMI patients under the study conditions.
• The lack of benefit may be attributed to celiprolol's strong ISA and lower-than-expected blood levels in AMI patients compared to healthy volunteers.